https://doi.org/10.5217/ir.2024.00118 • Intest Res 2025;23(3):358-371

Supplementary Table 6. At 6-, 12-, 18-, and 24-Month Persistence of Second Line Treatment in Patients with Crohn's Disease or Ulcerative Colitis

Index treatment	6 mo persistence with ≥ 6 mo continuous observation		12 mo persistence with ≥ 12 mo continuous observation		18 mo persistence with ≥ 18 mo continuous observation		24 mo persistence with ≥ 24 mo continuous observation	
	No. (%)	Total	No. (%)	Total	No. (%)	Total	No. (%)	Total
Crohn's disease								
Adalimumab	40 (87.0)	46	30 (76.9)	39	21 (70.0)	30	15 (60.0)	25
Infliximab	52 (92.9)	56	43 (87.8)	49	38 (86.4)	44	34 (85.0)	40
Vedolizumab	9 (100.0)	9	5 (83.3)	6	2 (50.0)	4	2 (50.0)	4
Ustekinumab	95 (95.0)	100	74 (91.4)	81	52 (85.2)	61	41 (85.4)	48
Total	196 (92.9)	211	152 (86.9)	175	113 (81.3)	139	92 (78.6)	117
Ulcerative colitis								
Adalimumab	45 (58.4)	77	30 (50.8)	59	24 (43.6)	55	18 (37.5)	48
Infliximab	71 (60.2)	118	51 (49.5)	103	38 (43.7)	87	27 (37.0)	73
Golimumab	71 (69.6)	102	51 (53.1)	96	32 (39.5)	81	18 (26.5)	68
Vedolizumab	94 (83.9)	112	67 (67.7)	99	46 (59.7)	77	35 (56.5)	62
Ustekinumab	94 (88.7)	106	62 (76.5)	81	29 (69.0)	42	14 (82.4)	17
Tofacitinib	57 (58.8)	97	48 (55.8)	86	35 (55.6)	63	27 (54.0)	50
Total	432 (70.6)	612	309 (59.0)	524	204 (50.4)	405	139 (43.7)	318